Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06614205
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-06-06
Brief Title:
Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DATUM
Brief Summary:
The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas
Detailed Description:
Dosimetry is essential for Peptide Receptor Radionuclide Therapy PRRT of meningiomas to predict efficacy and dose-effect relationships at the individual level and to move towards personalized medicine Due to the increasing therapeutic applications of Lutathera the European Association of Nuclear Medicine EANM recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues Nevertheless despite these recommendations the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic which has not enabled us to clearly determine the dose delivered to the meningioma lesion in these treatments and the possible dose-response relationship in this type of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None